About: Pharmacokinetics and Pharmacodynamics of Methotrexate in Non-Neoplastic Diseases     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

AttributesValues
rdf:type
Description
  • Terapie nízkými pulzními dávkami metotrexátu (LDMTX) je účinná v léčbě autoimunitních a lymfoproliferativních onemocnění. Farmakokinetika LDMTX je individuálně variabilní a vede k odlišné systemické expozici léčivu a variabilnímu léčebnému)toxickému účinku a pacienta. V případě lupenky, farmakokinetická/farmakodynamická analýza naší studie prokázala vysoce relevantní inverzní závislost mezi PASI (vyjádřené jako procento počáteční hodnoty) a steady-state AUCMTX (oblast pod křivkou plazmatických koncentrací metotrexátu). Výsledky této studie naznačují, že steady-state AUCTMX hodnota 700 nmol - h/l a vyšší se pojí s daleko vyšší účinností při léčbě lupenky než nižší hodnoty. Předběžné výsledky naší následující studie ukazují statisticky vyšší vznik nežádoucích účinků závislých na maximální plazmatické koncentraci léčiva. (cs)
  • Low dose pulse methotrexate (LDMTX) therapy has become effective in the treatment of autoimmune and lymphoproliferative diseases. The pharmacokinetics of LDMTX is individually highly variable, resulting in a different systemic exposure to the drug and a variable therapeutic/toxic effect in patients. In the case of psoriasis, pharmacokinetic/pharmacodynamic analysis in our local study revealed a highly significant inverse relationship between PASI (expressed as a percent of the initial value) and a steady-state AUCMTX (area under the curve of methotrexate plasma concentrations. The results of this study suggest that a steady-state AUCMTX value of 700 nmol - h/L and higher are associated with a significantly better success rate of antipsoriatic therapy than lower values. The preliminary results in our follow-up study suggest the statistically higher incidence of unwanted effects depending on maximum plasma concentration of the drug.
  • Low dose pulse methotrexate (LDMTX) therapy has become effective in the treatment of autoimmune and lymphoproliferative diseases. The pharmacokinetics of LDMTX is individually highly variable, resulting in a different systemic exposure to the drug and a variable therapeutic/toxic effect in patients. In the case of psoriasis, pharmacokinetic/pharmacodynamic analysis in our local study revealed a highly significant inverse relationship between PASI (expressed as a percent of the initial value) and a steady-state AUCMTX (area under the curve of methotrexate plasma concentrations. The results of this study suggest that a steady-state AUCMTX value of 700 nmol - h/L and higher are associated with a significantly better success rate of antipsoriatic therapy than lower values. The preliminary results in our follow-up study suggest the statistically higher incidence of unwanted effects depending on maximum plasma concentration of the drug. (en)
Title
  • Pharmacokinetics and Pharmacodynamics of Methotrexate in Non-Neoplastic Diseases
  • Pharmacokinetics and Pharmacodynamics of Methotrexate in Non-Neoplastic Diseases (en)
  • Farmakokinetika a farmakodynamika metotrexátu u nenádorových onemocněních (cs)
skos:prefLabel
  • Pharmacokinetics and Pharmacodynamics of Methotrexate in Non-Neoplastic Diseases
  • Pharmacokinetics and Pharmacodynamics of Methotrexate in Non-Neoplastic Diseases (en)
  • Farmakokinetika a farmakodynamika metotrexátu u nenádorových onemocněních (cs)
skos:notation
  • RIV/00216208:11150/03:00004324!RIV08-MSM-11150___
http://linked.open.../vavai/riv/strany
  • 139;151
http://linked.open...avai/riv/aktivita
http://linked.open...avai/riv/aktivity
  • S
http://linked.open...iv/cisloPeriodika
  • 2
http://linked.open...vai/riv/dodaniDat
http://linked.open...aciTvurceVysledku
http://linked.open.../riv/druhVysledku
http://linked.open...iv/duvernostUdaju
http://linked.open...titaPredkladatele
http://linked.open...dnocenehoVysledku
  • 620748
http://linked.open...ai/riv/idVysledku
  • RIV/00216208:11150/03:00004324
http://linked.open...riv/jazykVysledku
http://linked.open.../riv/klicovaSlova
  • Pharmacokinetics; Pharmacodynamics; Methotrexate; Non-Neoplastic; Diseases (en)
http://linked.open.../riv/klicoveSlovo
http://linked.open...odStatuVydavatele
  • NZ - Nový Zéland
http://linked.open...ontrolniKodProRIV
  • [C9E080404FA2]
http://linked.open...i/riv/nazevZdroje
  • Clinical Pharmacokinetic
http://linked.open...in/vavai/riv/obor
http://linked.open...ichTvurcuVysledku
http://linked.open...cetTvurcuVysledku
http://linked.open...UplatneniVysledku
http://linked.open...v/svazekPeriodika
  • 42
http://linked.open...iv/tvurceVysledku
  • Chládek, Jaroslav
  • Martínková, Jiřina
issn
  • 0312-5963
number of pages
http://localhost/t...ganizacniJednotka
  • 11150
Faceted Search & Find service v1.16.118 as of Jun 21 2024


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 48 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software